Physician profile
Mark Dashevskiy
NPI 1649379934
$2,221.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,972 · 2020: $125 · 2021: $125.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $405.48 | 2019 | |
| Pfizer INC. | $375.38 | 2019-2020 | |
| Amarin Pharma, INC. | $374.69 | 2019 | |
| Allergan, INC. | $263.38 | 2019 | |
| Dova Pharmaceuticals | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2019 | |
| Amgen INC. | $124.97 | 2019 | |
| Merck Sharp & Dohme LLC | $124.92 | 2019 | |
| Abbvie INC. | $124.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $116.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.54 | 2019 | |
| Acorda Therapeutics, INC | $15.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dashevskiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.